JPMorgan Asset Management Form 8.3 - Pfizer Inc (6640G)
24 11월 2015 - 12:31AM
UK Regulatory
TIDMPFZ
RNS Number : 6640G
JPMorgan Asset Management
23 November 2015
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2007 (AS AMENDED)
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing JPMorgan Asset Management
(Note 1)
-------------------------------------- --------------------------
Company dealt in Pfizer Inc.
-------------------------------------- --------------------------
Class of relevant security Ordinary Shares
to which the dealings
being disclosed relate
(Note 2)
-------------------------------------- --------------------------
Date of dealing 20 November 2015
-------------------------------------- --------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
--------------------------------- -------------------- -------------
Number (%) Number (%)
--------------------------------- ------------- ----- ------- ----
91,116,535
(1) Relevant securities * 1.48
--------------------------------- ------------- ----- ------- ----
(2) Derivatives (other
than options) 208,388 0.00
--------------------------------- ------------- ----- ------- ----
(3) Options and agreements
to purchase/sell
--------------------------------- ------------- ----- ------- ----
91,324,923
Total * 1.48
--------------------------------- ------------- ----- ------- ----
*In addition to the dealings in section 3, there is an increase
in the holding of 341 shares due to a transfer.
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
-------------------------------- ------------- -------------
Number (%) Number (%)
-------------------------------- ------- ---- ------- ----
(1) Relevant securities
-------------------------------- ------- ---- ------- ----
(2) Derivatives (other
than options)
-------------------------------- ------- ---- ------- ----
(3) Options and agreements
to purchase/sell
-------------------------------- ------- ---- ------- ----
Total
-------------------------------- ------- ---- ------- ----
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant Price per unit
securities (USD)
-------------- ------------------- ---------------
Purchase 33 32.2572 USD
Purchase 263 32.2969 USD
Purchase 14 32.3000 USD
Purchase 30,729 32.3999 USD
Purchase 2,139 32.4272 USD
Purchase 1,950,000 32.4355 USD
Sale 706 32.1914 USD
Sale 847 32.2170 USD
Sale 3 32.2670 USD
Sale 23 32.2680 USD
Sale 133 32.2690 USD
Sale 1 32.2700 USD
Sale 3 32.3370 USD
Sale 33 32.3380 USD
Sale 45 32.3390 USD
Sale 2 32.3400 USD
Sale 145 32.3700 USD
Sale 316 32.3710 USD
Sale 861 32.3720 USD
Sale 145 32.3847 USD
Sale 566 32.4280 USD
Sale 132 32.4290 USD
Sale 15 32.4300 USD
Sale 3 32.4370 USD
Sale 58 32.4390 USD
Sale 15 32.4400 USD
-------------- ------------------- ---------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant Price per unit
e.g. CFD (Note 6) securities (Note (Note 5)
7)
-------------- ---------------------- ------------------- ---------------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, Number of Exercise Type, Expiry Option
e.g. call selling, securities price e.g. American, date money
option purchasing, to which European paid/received
varying the option etc. per unit
etc. relates (Note (Note 5)
7)
-------------- ------------- --------------- --------- ---------------- ------- ---------------
(ii) Exercising
Product name, e.g. Number of securities Exercise price per
call option unit (Note 5)
------------------- --------------------- -------------------
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction Details Price per unit (if
(Note 8) applicable) (Note
5)
---------------------- -------- -------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating
to the voting rights of any relevant securities under
any option referred to on this form or relating to the
voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred
to on this form is referenced. If none, this should
be stated.
-------------------------------------------------------------
Is a Supplemental Form 8 attached? NO
(Note 9)
Date of disclosure 23 November 2015
--------------------------------------------- ----------------------
Contact name Evangelos Galiatsatos
--------------------------------------------- ----------------------
Telephone number 0207 742 6148
--------------------------------------------- ----------------------
If a connected EFM, name of offeree/offeror N/A
with which connected
--------------------------------------------- ----------------------
If a connected EFM, state nature N/A
of connection (Note 10)
--------------------------------------------- ----------------------
The Notes on Form 8.3 can be viewed on the Panel's website at
www.irishtakeoverpanel.ie.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ISEBJBATMBTTBPA
(END) Dow Jones Newswires
November 23, 2015 10:31 ET (15:31 GMT)
Pfizer (LSE:PFZ)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Pfizer (LSE:PFZ)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
